Recovery of Mycobacterium elephantis from Sputum of a Patient in Belgium

Mycobacterium elephantis was isolated from a human respi- ratory specimen in April 1999, demonstrating its presence in Europe. The biochemical reaction results, antimicrobial sus- ceptibility pattern, and sequence data for this strain are all in agreement with those of M. elephantis strains isolated previ- ously from other continents (2, 4). A 79-year-old man from rural Belgium with watery diarrhea (blood and mucus absent) and palpitations was hospitalized. Empirical treatment with ciprofloxacin for an upper respira- tory tract infection was noted in his recent medical history. A diagnosis of enteritis (no pathogen isolated) was made, and a cardiovascular evaluation demonstrated ventricular or ex- traventricular extrasystoles and mitral valve insufficiency. A mycobacterium strain (S2257) was isolated from sputum and referred to our laboratory for identification and suscepti- bility testing. Subculture of the strain was done on Lowenstein-Jensen and Ogawa media. Both media were incubated at 35°C in CO2 atmosphere. S2257 took more than 3 days to grow and was nonchromogenic. Staining the culture with Auramin O con- firmed the presence of acid-fast bacilli. A limited number of biochemical tests were performed: catalase activity (semiquan- titative), production of urease, nitrate reduction, and Tween 80 hydrolysis (3). The results (all positive) suggested that this strain belonged to the Mycobacterium triviale-nonchromogeni- cum-terrae complex. Growth of the strain on Middlebrook 7H10 medium was the starting point for gas-liquid chromatog- raphy of cellular fatty acids (Sherlock Microbial Identification System (MIS); MIDI, Inc., Newark, Del.). The fatty acid methyl ester profile obtained was compared with those in the MIS database and were similar to Mycobacterium avium-intra- cellulare (similarity coefficient, 0.406 to 0.655). Susceptibility testing was done on Middlebrook 7H10 me- dium supplemented with isoniazide (0.2 and 1 g/ml), strep- tomycin (2 g/ml), ethambutol (5 and 10 g/ml), rifampin (1 g/ml), rifabutin (1 g/ml), kanamycin (5 g/ml), capreomycin (10 g/ml), cycloserine (30 g/ml), and clarithromycin (4 g/ ml). These plates were incubated in the dark in a humid CO2 incubator at 35°C for 3 weeks. The antibiotic profile was unlike that known for Mycobacterium avium-intracellulare, since S2257 was susceptible to isoniazide (highest concentration), streptomycin, kanamycin, capreomycin, cycloserine, and clar- ithromycin. Since Accuprobes (Gen-Probe) for the M. avium-intracellu- lare complex are not routinely used in our laboratory, a se- quence analysis (EUROGENTEC, Seraing, Belgium) of part of the amplified 16S rRNA gene of S2257 was performed as described previously (1). The sequence was compared against those available from the National Center for Biotechnology Information database (www.ncbi.nlm.nih.gov/entrez), and a similarity index was determined using Gene Compar (Applied Maths, Sint-Martens-Latem, Belgium). There was a 99.8% similarity to M. elephantis (accession number AJ010747). Our identification was confirmed by Dr. E. C. Bottger (Institut fur Medizinische Mikrobiologie, Hannover, Germany). The patient had not experienced any contact with animals and specifically not with elephants from which the first strain of M. elephantis was isolated (2). However, there was a history of respiratory tract infection and enteritis. M. elephantis was iso- lated only once (but only one mycobacterium culture was per- formed). We conclude that further studies are required into the ori- gin, infectiveness, and clinical significance of M. elephantis .I n general, clinicians should be aware of the clinical relevance of nontuberculous mycobacterial species, and laboratories should use more advanced methods, including molecular techniques for the identification of mycobacteria not readily identified by standard methods.